About: Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN) Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)
Creator	Zweegman, Sonja Moreau, Philippe Van De Donk, Niels Annette, • Avet-Loiseau, Hervé Boccadoro, Mario Cook, • Dimopoulos, A Engelhardt, Monika Gay, Francesca Hajek, Roman Hermann Einsele, • Ludwig, • Mateos, Maria-Victoria Meletios, • Ntanasis-Stathopoulos, Ioannis San, Jesus Sonneveld, Pieter Terpos, Evangelos Vangsted, Juul
Source	Medline; PMC
abstract	Patients with multiple myeloma (MM) seem to be at increased risk for more severe COVID-19 infection and associated complications due to their immunocompromised state, the older age and comorbidities. The European Myeloma Network has provided an expert consensus statement in order to guide therapeutic decisions in the era of the COVID-19 pandemic. Patient education for personal hygiene and social distancing measures, along with treatment individualization, telemedicine and continuous surveillance for early diagnosis of COVID-19 are essential. In countries or local communities where COVID-19 infection is widely spread, MM patients should have a PCR test of nasopharyngeal swab for SARS-CoV-2 before hospital admission, starting a new treatment line, cell apheresis or ASCT in order to avoid ward or community spread and infections. Oral agent-based regimens should be considered, especially for the elderly and frail patients with standard risk disease, whereas de-intensified regimens for dexamethasone, bortezomib, carfilzomib and daratumumab should be used based on patient risk and response. Treatment initiation should not be postponed for patients with end organ damage, myeloma emergencies and aggressive relapses. Autologous (and especially allogeneic) transplantation should be delayed and extended induction should be administered, especially in standard risk patients and those with adequate MM response to induction. Watchful waiting should be considered for standard risk relapsed patients with low tumor burden, and slow biochemical relapses. The conduction of clinical trials should continue with appropriate adaptations to the current circumstances. Patients with MM and symptomatic COVID-19 disease should interrupt anti-myeloma treatment until recovery. For patients with positive PCR test for SARS-CoV-2, but with no symptoms for COVID-19, a 14-day quarantine should be considered if myeloma-related events allow the delay of treatment. The need for surveillance for drug interactions due to polypharmacy is highlighted. The participation in international COVID-19 cancer registries is greatly encouraged.
has issue date	2020-05-22(xsd:dateTime)
bibo:doi	10.1038/s41375-020-0876-z
bibo:pmid	32444866
has license	no-cc
sha1sum (hex)	54e0488bd8e6593ca3915b10846a5e45e01a3388
schema:url	https://doi.org/10.1038/s41375-020-0876-z
resource representing a document's title	Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)
has PubMed Central identifier	PMC7244257
has PubMed identifier	32444866
schema:publication	Leukemia
resource representing a document's body	covid:54e0488bd8e6593ca3915b10846a5e45e01a3388#body_text
is schema:about of	named entity 'slow' named entity 'PCR' named entity 'SARS-CoV-2' named entity 'risk' named entity 'elderly' named entity 'induction' named entity 'recovery' named entity 'diagnosis' named entity 'burden' named entity 'myeloma' named entity 'avoid' named entity 'PCR' named entity 'Network' named entity 'myeloma' named entity 'CARFILZOMIB' named entity 'STARTING' named entity 'CLINICAL TRIALS' named entity 'STATE' named entity 'DRUG INTERACTIONS' named entity 'BUT' named entity 'TO AVOID' named entity 'PERSONAL HYGIENE' named entity 'WATCHFUL WAITING' named entity 'ADEQUATE' named entity 'INCREASED RISK' named entity 'COMMUNITIES' named entity 'CONSENSUS' named entity 'HOSPITAL ADMISSION' named entity 'CONTINUOUS' named entity 'BIOCHEMICAL' named entity 'WIDELY SPREAD' named entity 'LINE' named entity 'CONDUCTION' named entity 'END ORGAN DAMAGE' named entity 'STATEMENT' named entity 'WHERE' named entity 'DARATUMUMAB' named entity 'Patients' named entity 'comorbidities' named entity 'infection' named entity 'relapsed' named entity 'emergencies' named entity 'severe' named entity 'era' named entity 'risk' named entity 'carfilzomib' named entity 'response' named entity 'age' named entity 'order' named entity 'Oral' named entity 'SARS-CoV-2' named entity 'COVID-19 disease' named entity 'clinical trials' named entity 'apheresis' named entity 'COVID-19 infection' named entity 'personal hygiene' named entity 'comorbidities' named entity 'polypharmacy' named entity 'Watchful waiting' named entity 'test' named entity 'The' named entity 'lenalidomide'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software